Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial - PubMed
7 hours ago
- #Chronic Kidney Disease
- #Canagliflozin
- #Type 2 Diabetes
- Canagliflozin, an SGLT2 inhibitor, was studied for its cardiorenal effects in type 2 diabetes patients with chronic kidney disease (CKD).
- Dietary sodium intake was categorized into low-normal sodium (LNS) and high sodium (HS) groups, with LNS linked to increased heart failure and cardiovascular death risk in the placebo group.
- Canagliflozin significantly reduced the risk of heart failure and cardiovascular death in the LNS group but showed no significant effect in the HS group.
- Renal outcomes were unaffected by sodium intake, but canagliflozin provided renal protection regardless of sodium levels.
- All-cause mortality was not influenced by either sodium intake or canagliflozin treatment.
- The study suggests that canagliflozin mitigates cardiovascular risks associated with low-normal sodium intake while offering consistent renal benefits.